Risk Factors for Sever Forms of COVID-19 - A Second Level Moroccan Hospital Experience
PDF

How to Cite

1.
Taoufiq R, Essabbani M, Mouhib NE, Mokahli S, Bougar S, Oubejja NE. Risk Factors for Sever Forms of COVID-19 - A Second Level Moroccan Hospital Experience. ATD [Internet]. 2021 Sep. 28 [cited 2021 Oct. 26];2021. Available from: https://mbmj.org/index.php/atd/article/view/496

Abstract

The new coronavirus (2019-nCoV) has caused the death of more than 1.68 million patients worldwide, including 6,909 deaths registered in Morocco until 12/20/2020. The main objective of this study is to investigate epidemiological, clinical, and paraclinical factors predicting progression to the severity in order to identify patients at risk and adopt strategies for individualized management.
We conduct this observational, descriptive, and analytical study from 01/09/2020 to 25/12/2020, at AL FARABI regional hospital in Oujda. 567 patients were eligible for our study out of 2000 patients who were admitted since our first case on April 2020. Our sample was divided into two groups based on pulse oxygen saturation on admission. We identified 294 as a Severe/Critical case and 273 as a Mild/Moderate form on admission. The mean age was significantly higher in the severe group (63.28 ± 12.4 vs 55.13 ± 17.2). The sex ratio M/F was 0.87. Compared with non-severe cases, severe cases exhibited more comorbidities, including diabetes (60.4% vs 39.6%; P 0.003), and hypertension (63.6% vs 26.4%; P 0.002). Several biological parameters were associated with disease severity in univariate analysis, the most important being lymphopenia, elevated C-reactive protein, and ferritin levels. lymphopenia (OR 3.76; 95% CI, 4.25-9.23), elevated C-reactive protein (OR, 5.7; 95% CI, 3.84-8.48) ferritin levels (OR, 3.6; 95% CI, 1.64-7.89) were significantly associated with severe cases of COVID-19. Mortality is 2.9% for all of our patients; it increases to 4.5% if we consider severe cases only. Identification and evaluation of epidemiological, clinical, and paraclinical parameters are important to identify patients at high risk of SARS-COV2 severity to guide treatment.

https://doi.org/10.15342/atd.2021.496
PDF

References

- El Zowalaty ME, Järhult JD. From SARS to COVID-19: A previously unknown SARSrelated coronavirus (SARS-CoV-2) of pandemic potential infecting humans - Call for a One Health approach. One health (Amsterdam, Netherlands) 2020;9:100124.

- Gorbalenya A.E., Baker S.C., Baric R.S. (sous presse); BioRxiv: 2020. Severe acute respiratory syndrome-related coronavirus: the species and its viruses – a statement of the coronavirus study group. [Google Scholar]

- Dae-Gyun A., Hye-Jin S., Mi-Hwa K. Current status of epidemiology, diagnosis, therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19) J. Microbiol. Biotechnol. 2020;30(3):313–324. [PubMed] [Google Scholar]

- Njenga, M. K., Dawa, J., Nanyingi, M., Gachohi, J., Ngere, I., Letko, M., Otieno, C. F., Gunn, B. M., & Osoro, E. (2020). Why is There Low Morbidity and Mortality of COVID-19 in Africa?, The American Journal of Tropical Medicine and Hygiene, 103(2), 564-569. Retrieved May 27, 2021, from https://www.ajtmh.org/view/journals/tpmd/103/2/article-p564.xml

- National Health Commission. Chinese Clinical Guidance For COVID-19 Pneumonia Diagnosis and Treatment- American College of Cardiology (acc.org) (7th version).

- ChenN, ZhouM,DongX, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia inWuhan, China: a descriptive study. Lancet. 2020;395:507–513.

- Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology. 2020;295:202–207.

- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62. doi:10.1016/S0140- 6736(20)30566-3.

- To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020. doi:10.1016/s1473-3099(20)30196-1.

- Hong KH, Choi JP, Hong SH, Lee J, Kwon JS, Kim SM, et al. Predictors of mortality in Middle East respiratory syndrome (MERS). Thorax 2018;73:286– 9. doi:10.1136/thoraxjnl-2016-209313.

- Choi KW, Chau TN, Tsang O, Tso E, Chiu MC, Tong WL, et al. Outcomes and Prognostic Factors in 267 Patients with Severe Acute Respiratory Syndrome in Hong Kong. Ann Intern Med 2003;139. doi:10.7326/0003-4819-139-9-

- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia inWuhan, China. JAMA. 2020.

- The Lancet. The gendered dimensions of COVID-19. Lancet 2020;395:1168. doi:10.1016/S0140-6736(20)30823-0.

- Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med 2020;8:e20. doi:10.1016/S2213-2600(20)30117-X.

- Zheng Q-L, Duan T, Jin L-P. Single-cell RNA expression profiling of ACE2 and AXL in the human maternal–Fetal interface. Reprod Dev Med 2020;4:7. doi:10.4103/2096-2924.278679.

- Xiaochen Li, Shuyun Xu, Muqing Yu, Ke Wang, Yu Tao, Ying Zhou, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan J ALLERGY CLIN IMMUNOL 2020; 146: 1. doi.org/10.1016/j.jaci.2020.04.006

- McGurnaghan, S. J., Weir, A., Bishop, J., Kennedy, S., Blackbourn, L. A. K., McAllister, et al. (2021). Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. The Lancet Diabetes & Endocrinology, 9(2), 82–93.

- Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020. doi:10.1007/s00392-020-01626-9.

- Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, Weng Z, Yang L. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. Int J Infect Dis. 2020 Jul;96:131-135. doi: 10.1016/j.ijid.2020.04.086. Epub 2020 May 4. PMID: 32376308; PMCID: PMC7196544.

- Li, K., Wu, J., Wu, F., Guo, D., Chen, L., Fang, Z., & Li, C. (2020). The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia. Investigative radiology, 55(6), 327–331.

- Henry BM, De Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020 Apr 10;58: 1021–8.

- Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020 Mar 3;58:1131–4.

- Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, PolitouM, et al. Hematological findings and complications of COVID-19. American Journal of Hematology [Internet]. n/a(n/a). Available from: https://doi.org/10.1002/ajh.25829

- Zhaohai Zheng a , b , 1 , Fang Peng a , 1 , Buyun Xu a , Jingjing Zhao a , b , Huahua Liu c , Jiahao Peng d, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. Journal of Infection 81 (2020) e16–e25.

- Haick AK, Rzepka JP, Brandon E, Balemba OB, Miura TA. Neutrophils are needed for an effective immune response against pulmonary rat coronavirus infection, but also contribute to pathology. J Gen Virol 2014;95:578e90. https://doi.org/10.1099/vir.0.061986-0.

- Didangelos A. COVID-19 hyperinflammation: what about neutrophils? mSphere 2020;5(3). https://doi.org/10.1128/mSphere.00367-20.

- Aditya A, Prakash KJ, Abhishek K.Differential white blood cell count in the COVID-19 : A cross-sectional study of 148 patients.Diabetes and metabolic syndrome : clinical research and reviews 14 (2020) 2020-2102.

- Matsumoto H, Kasai T, Sato A, Ishiwata S, Yatsu S, Shitara J, et al. Associa- tion between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure. Heart Vessels 2019;34(12):1961–8, http://dx.doi.org/10.1007/s00380-019-01435-9.

- Chalmers S, Khawaja A, Wieruszewski PM, Gajic O, Odeyemi Y. Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: the role of inflammatory biomarkers. World J Crit Care Med 2019;8(5):59–71, http://dx.doi.org/10.5492/wjccm.v8.i5.59.

- Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible?. Lancet Gastroenterol Hepatol. 2020;5:335–7.

- Thirumalaisamy P Velavan, Christian G Meyer. Mild Versus severe COVID-19 : Laboratory markers. International Journal of Infectious Diseases. 95(2020) 304-307.

- Ruscitti P, Berardicurti O, Di Benedetto P et al. Severe COVID-19, another piece in the puzzle of the hyperferritinemic syndrome. An immunomodulatory perspective to alleviate the storm. Front Immunol 2020 ; 11 :1130.

- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.[J]. Lancet 2020; 395 (10223):497–506. doi: 10. 1016/s0140-6736(20)30183-5 .

- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan. China: a retrospective cohort study. Lancet 2020 Mar 28;395(10229):1054-1062.

- Koo HJ, Lim S, Choe J, et al. Radiographic and CT features of viral pneumonia. Radiographics. 2018;38:719–739.

- Franquet T. Imaging of pulmonary viral pneumonia. Radiology. 2011;260:18–39.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2021 Taoufiq R et al.

Metrics

Metrics Loading ...